| GTO ID | GTC3540 |
| Trial ID | NCT05984927 |
| Disease | Age-Related Macular Degeneration |
| Therapy | Gene transfer |
| Treatment | NG101 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration |
| Year | 2023 |
| Country | Canada |
| Company sponsor | Neuracle Genetics, Inc |
| Other ID(s) | NG101WA-01 |
| Vector information | |||||
|
|||||
| Cohort1: dose level 1 | |||||||
|
|||||||
| Cohort2: dose level 2 | |||||||
|
|||||||
| Cohort3: dose level 3 | |||||||
|
|||||||